SEC recommends Phase 1 clinical trials of Reliance's Covid Vaccine candidate

New Delhi [India], August 27 (ANI): The Subject Expert Committee (SEC) has recommended Phase 1 clinical trials of Reliance's recombinant COVID-19 vaccine candidate.

Related Keywords

Delhi ,India ,New Delhi ,Tamil Nadu ,Zydus Cadila ,Serum Institute Of India Covishield ,Mukesh Reliance Life Sciences ,Reliance Life Sciences ,Expert Committee ,Subject Expert Committee ,Mukesh Ambani Owned Reliance Life Sciences ,Drug Controller General ,Andhra Pradesh ,Emergency Use Authorization ,Serum Institute ,Bharat Biotech ,Reliance Covid 19 Vaccine ,Clinical Trail ,Cgi ,